Anti-B3GN9/ B3GNT9 functional antibody
Anti-B3GN9/ B3GNT9 functional antibody for cell culture, ELISA & in-vivo assay
Go to B3GNT9/B3GNT9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE1664-Ab-1/ GM-Tg-hg-SE1664-Ab-2 | Anti-Human B3GNT9 monoclonal antibody | Human |
| GM-Tg-rg-SE1664-Ab-1/ GM-Tg-rg-SE1664-Ab-2 | Anti-Rat B3GNT9 monoclonal antibody | Rat |
| GM-Tg-mg-SE1664-Ab-1/ GM-Tg-mg-SE1664-Ab-2 | Anti-Mouse B3GNT9 monoclonal antibody | Mouse |
| GM-Tg-cynog-SE1664-Ab-1/ GM-Tg-cynog-SE1664-Ab-2 | Anti-Cynomolgus/ Rhesus macaque B3GNT9 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE1664-Ab-1/ GM-Tg-felg-SE1664-Ab-2 | Anti-Feline B3GNT9 monoclonal antibody | Feline |
| GM-Tg-cang-SE1664-Ab-1/ GM-Tg-cang-SE1664-Ab-2 | Anti-Canine B3GNT9 monoclonal antibody | Canine |
| GM-Tg-bovg-SE1664-Ab-1/ GM-Tg-bovg-SE1664-Ab-2 | Anti-Bovine B3GNT9 monoclonal antibody | Bovine |
| GM-Tg-equg-SE1664-Ab-1/ GM-Tg-equg-SE1664-Ab-2 | Anti-Equine B3GNT9 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-SE1664-Ab-1/ GM-Tg-hg-SE1664-Ab-2; GM-Tg-rg-SE1664-Ab-1/ GM-Tg-rg-SE1664-Ab-2; GM-Tg-mg-SE1664-Ab-1/ GM-Tg-mg-SE1664-Ab-2; GM-Tg-cynog-SE1664-Ab-1/ GM-Tg-cynog-SE1664-Ab-2; GM-Tg-felg-SE1664-Ab-1/ GM-Tg-felg-SE1664-Ab-2; GM-Tg-cang-SE1664-Ab-1/ GM-Tg-cang-SE1664-Ab-2; GM-Tg-bovg-SE1664-Ab-1/ GM-Tg-bovg-SE1664-Ab-2; GM-Tg-equg-SE1664-Ab-1/ GM-Tg-equg-SE1664-Ab-2 |
| Products Name | Anti-B3GNT9 monoclonal antibody |
| Format | mab |
| Target Name | B3GNT9 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-B3GNT9 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-SE1664-Ag-1 | Recombinant multi-species B3GN9/ B3GNT9 protein |
Target information
| Target ID | GM-SE1664 |
| Target Name | B3GNT9 |
| Gene ID | 84752,97440,291958,698037,489767,101097530,614717,100065795 |
| Gene Symbol and Synonyms | 3-Gn-T9,B3GNT9,B3gnt9-ps,beta-1,beta3Gn-T9,BGnT-9,RGD1310170 |
| Uniprot Accession | Q6UX72,Q17QZ8 |
| Uniprot Entry Name | B3GN9_HUMAN,B3GN9_BOVIN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000237172 |
| Target Classification | N/A |
The target: B3GNT9, gene name: B3GNT9, also named as . Predicted to enable UDP-glycosyltransferase activity. Predicted to be involved in poly-N-acetyllactosamine biosynthetic process. Predicted to be integral component of membrane. Predicted to be active in Golgi membrane. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

